Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington's Disease-Related Chorea.

Literature DB >> 19750050

Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington's Disease-Related Chorea.

Tatiana Yero, Jose A Rey.

Abstract

Entities: Chemical Disease

Keywords: Huntington’s chorea; Huntington’s disease; Xenazine; chorea; tetrabenazine

Year: 2008 PMID： 19750050 PMCID： PMC2730806

Source DB: PubMed Journal: P T ISSN： 1052-1372

× No keyword cloud information.

14 in total

Review 1. Neurotransmitter transporters in the central nervous system.

Authors: J Masson; C Sagné; M Hamon; S El Mestikawy
Journal: Pharmacol Rev Date: 1999-09 Impact factor: 25.468

Review 2. A molecular glimpse of vesicular monoamine transporters.

Authors: S Schuldiner
Journal: J Neurochem Date: 1994-06 Impact factor: 5.372

3. Tetrabenazine induces acute dystonic reactions.

Authors: R E Burke; A Reches; M M Traub; J Ilson; M Swash; S Fahn
Journal: Ann Neurol Date: 1985-02 Impact factor: 10.422

4. Tetrabenazine has properties of a dopamine receptor antagonist.

Authors: I S Login; M J Cronin; R M MacLeod
Journal: Ann Neurol Date: 1982-09 Impact factor: 10.422

5. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies.

Authors: R Mehvar; F Jamali; M W Watson; D Skelton
Journal: Drug Metab Dispos Date: 1987 Mar-Apr Impact factor: 3.922

6. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease.

Authors: Samuel Frank; William Ondo; Stanley Fahn; Christine Hunter; David Oakes; Sandra Plumb; Frederick Marshall; Ira Shoulson; Shirley Eberly; Francis Walker; Stewart Factor; Vicki Hunt; Aileen Shinaman; Joseph Jankovic
Journal: Clin Neuropharmacol Date: 2008 May-Jun Impact factor: 1.592

7. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain.

Authors: A Reches; R E Burke; C M Kuhn; M N Hassan; V R Jackson; S Fahn
Journal: J Pharmacol Exp Ther Date: 1983-06 Impact factor: 4.030

Review 8. Tetrabenazine in the treatment of hyperkinetic movement disorders.

Authors: Christopher Kenney; Joseph Jankovic
Journal: Expert Rev Neurother Date: 2006-01 Impact factor: 4.618

9. The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders.

Authors: M S Roberts; S McLean; K S Millingen; H M Galloway
Journal: Eur J Clin Pharmacol Date: 1986 Impact factor: 2.953

10. Determination of therapeutic plasma concentrations of tetrabenazine and an active metabolite by high-performance liquid chromatography.

Authors: M S Roberts; H M Watson; S McLean; K S Millingen
Journal: J Chromatogr Date: 1981-11-13

20 in total

Review 1. Orphan drug development: the increasing role of clinical pharmacology.

Authors: Mariam A Ahmed; Malek Okour; Richard Brundage; Reena V Kartha
Journal: J Pharmacokinet Pharmacodyn Date: 2019-07-23 Impact factor: 2.745

2. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.

Authors: Emily Mitchell Sontag; Gregor P Lotz; Namita Agrawal; Andrew Tran; Rebecca Aron; Guocheng Yang; Mihaela Necula; Alice Lau; Steven Finkbeiner; Charles Glabe; J Lawrence Marsh; Paul J Muchowski; Leslie M Thompson
Journal: J Neurosci Date: 2012-08-08 Impact factor: 6.167

3. Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and clinicians.

Authors: Carey Wexler Sherman; Ravi Iyer; Victor Abler; Alexandria Antonelli; Noelle E Carlozzi
Journal: Neuropsychol Rehabil Date: 2019-03-08 Impact factor: 2.868

4. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.

Authors: A C Meyer; D B Horton; N M Neugebauer; T E Wooters; J R Nickell; L P Dwoskin; M T Bardo
Journal: Neuropharmacology Date: 2011-06-12 Impact factor: 5.250

5. Quadriparesis and dysarthria due to tetrabenazine therapy in a child with rheumatic chorea.

Authors: Syed Ahmed Zaki; Vijay Lad; Preeti Shanbag
Journal: Indian J Pharmacol Date: 2011-09 Impact factor: 1.200

Review 6. A systematic review on the use of clozapine in treatment of tardive dyskinesia and tardive dystonia in patients with psychiatric disorders.

Authors: Jocelyn Wong; Tiffanie Pang; Natalie Kwok Wing Cheuk; Yingqi Liao; Tarun Bastiampillai; Sherry Kit Wa Chan
Journal: Psychopharmacology (Berl) Date: 2022-09-30 Impact factor: 4.415

Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington's Disease-Related Chorea.

Review 1. Neurotransmitter transporters in the central nervous system.

Review 2. A molecular glimpse of vesicular monoamine transporters.

3. Tetrabenazine induces acute dystonic reactions.

4. Tetrabenazine has properties of a dopamine receptor antagonist.

5. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies.

6. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease.

7. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain.

Review 8. Tetrabenazine in the treatment of hyperkinetic movement disorders.

9. The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders.

10. Determination of therapeutic plasma concentrations of tetrabenazine and an active metabolite by high-performance liquid chromatography.

Review 1. Orphan drug development: the increasing role of clinical pharmacology.

2. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.

3. Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and clinicians.

4. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.

5. Quadriparesis and dysarthria due to tetrabenazine therapy in a child with rheumatic chorea.

Review 6. A systematic review on the use of clozapine in treatment of tardive dyskinesia and tardive dystonia in patients with psychiatric disorders.

Review 7. Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Review 8. Tetrabenazine: Spotlight on Drug Review.

Review 9. A Brief Review on the Role of Vesicular Monoamine Transporter₂ Inhibitors in Hyperkinetic Movement Disorders.

10. Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect.

Review 1. Neurotransmitter transporters in the central nervous system.

Review 2. A molecular glimpse of vesicular monoamine transporters.

Review 8. Tetrabenazine in the treatment of hyperkinetic movement disorders.

Review 1. Orphan drug development: the increasing role of clinical pharmacology.

Review 6. A systematic review on the use of clozapine in treatment of tardive dyskinesia and tardive dystonia in patients with psychiatric disorders.

Review 7. Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Review 8. Tetrabenazine: Spotlight on Drug Review.

Review 9. A Brief Review on the Role of Vesicular Monoamine Transporter2 Inhibitors in Hyperkinetic Movement Disorders.

Review 9. A Brief Review on the Role of Vesicular Monoamine Transporter₂ Inhibitors in Hyperkinetic Movement Disorders.